Wegovy® (semaglutide injection) Receives Conditional Marketing Authorization from Health Canada as the First and Only Treatment for Adults with Non-Cirrhotic MASH, a Serious Liver Disease2025.12.15
Sogroya® (somapacitan injection) now available in Canada as the first and only once-weekly treatment for both children and adults living with growth hormone deficiency2025.10.15
Novo Nordisk Canada and Pocketpills Announce Collaboration to Provide Enhanced Online Pharmacy and Prescription Services and Support for Ozempic® and Wegovy®2025.09.18
Health Canada approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease2025.08.19
CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM2025.06.24
Higher dose of semaglutide provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA2025.06.23
Health Canada accepts semaglutide 2.4 mg, a GLP-1RA treatment for MASH, as a supplemental New Drug Submission under the Priority Review Policy2025.05.02
SCORE analysis of semaglutide 2.4 mg demonstrated risk reduction in cardiovascular events in a real-world setting2025.03.31
Semaglutide 2.4 mg reduces burden of total cardiovascular events in people with established cardiovascular disease and overweight or obesity2025.03.31
Growing Healthy Places: Mississauga to support children’s health and well-being across the city2025.03.20
Léger survey shows four out of five Quebecers call for greater support for obesity from the government and public health system2024.10.21
Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases2023.08.10
Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity2023.04.12
Creation of a National Training Program for Healthcare Professionals Involved in Obesity Prevention and Care2022.04.05
Continued Support for Banting and Best’s Insulin Discovery and Research at the University of Toronto
2021.04.12
Novo Nordisk and the University of Toronto announce joint 200 DKK million investment to address diabetes and chronic disease prevention 2021.02.24

Camp Huronda receives $1.5M donation to rebuild on-site medical centre

 2021.01.14
Camp Huronda infographic                                                                                                                                                    2021.01.14